期刊文献+

乳腺癌术后复发转移患者药学监护1例

Pharmaceutical Care for an Inpatient with Postoperative Recurrence and Metastasis of Breast Cancer
下载PDF
导出
摘要 目的:探讨1例乳腺癌术后复发转移患者的化疗方案及药学监护要点。方法临床药师密切结合患者病情,根据国内外治疗指南及相关文献报道,协助医生制定合理的药物治疗方案并及时向临床提供合理的用药建议。方法:临床药师密切结合患者病情,根据国内外治疗指南及相关文献报道,协助医生制定合理的药物治疗方案并及时向临床提供合理的用药建议。结果:患者的药物治疗方案合理有效。通过对化疗药物不良反应的监护,使化疗过程顺利进行。结论:临床药师应以患者为中心,实施个体化药学监护,实现用药的安全有效,尽量避免不良反应的发生。 Objective:To discuss the chemotherapy regimens and points of pharmaceutical care for the patient of postoperative recurrence and metastasis of breast cancer. Methods:Combining with patient 's condition closely,clinical pharmacists helped doctors to develop their rational drug treatment programs and provide reasonable suggestions for clinical physicians in time according to relevant literature reports and domestic and international treatment guidelines. Results:Medication regimens of patients were effective and rationa1. In the monitoring of adverse reactions of chemotherapeutics,chemotherapy of patient proceeded smoothly. Conclusion:Clinical pharmacists should take patients as the center and implement individualized pharmaceutical care,which could improve the safety and effectivity of the patients' medication as well as avoid the occurrence of adverse reactions.
出处 《药物流行病学杂志》 CAS 2014年第8期505-508,共4页 Chinese Journal of Pharmacoepidemiology
关键词 乳腺癌术后 CEF方案 心脏毒性 化疗相关性呕吐 药学监护 Postoperative breast cancer CEF Cardiotoxicity Chemotherapy-induced emesis Pharmaceutical care
  • 相关文献

参考文献13

  • 1Beata B, Joanna N. Prognostic potential of topoisomerase IIa and HER-2 in a retrospective analysis of early advanced breast caneer patients treated with adjuvant anthracycline chemotherapy[ J ]. Breast,2011,3 : 1-13.
  • 2Van Dongen JA, Voogd AC, Fentinan IS, et al. Long-term results of a randomized trial comparing breast conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer [ J ]. Trial, 2000,92 ( 14 ) : 1143- 1150.
  • 3Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009[J]. Annals of Oncology , 2009,20(8) :1319-1329.
  • 4涂小煌.乳腺癌的化疗方案[J].中国临床医生杂志,2011,39(7):9-11. 被引量:4
  • 5吴涛,倪多,朱丽萍,欧江华.乳腺癌术后化疗方案TAC与AC→T近期不良反应比较[J].新疆医科大学学报,2009,32(12):1712-1714. 被引量:8
  • 6胡夕春,王碧芸.转移性乳腺癌内科治疗进展[J].中国临床肿瘤学进展,2010,8:281-283.
  • 7颜士岩,范建高.抗肿瘤药物对肝脏的影响及其在肝病患者中的应用[J].世界临床药物,2011,32(9):513-517. 被引量:17
  • 8陈雅敏,邹琛.药物性肝损伤的因果评价方法[J].药物流行病学杂志,2011,20(3):152-155. 被引量:9
  • 9Voravud N, Phase II trial of ramosetron plus dexamethaso- nein the prevention of cisplatin-induced nausea and vomiting [ J]. MedAssoc Thai ,2005, 88 (12) : 1790-1796.
  • 10徐巍,刘晓琳,苏乐群,李宏建.一例蒽环类药物心脏毒性的用药分析[J].药品评价,2012,9(20):31-33. 被引量:2

二级参考文献58

  • 1王书杰,武永吉,沈悌.蒽环类药物的心脏毒性[J].医学研究杂志,2006,35(1):64-66. 被引量:36
  • 2王根菊,韩国荣.Amifostine在肿瘤化疗中作用的研究进展[J].东南大学学报(医学版),2006,25(2):139-142. 被引量:7
  • 3李文瑜,费洪文,陆泽生.无创监测表阿霉素心脏毒性-组织多普勒超声心动图[J].中国病理生理杂志,2006,22(10):1983-1986. 被引量:20
  • 4Edith A, Perez MD. TAC-A new standard in adjuvant therapy for breast cancer? [J]. Cancer Res, 2009,69:597-603.
  • 5Eiermann W, Pienkowski T , Crown J, et al. A phase Ⅲ randomized trial comparing docetaxel in combination with doxorubiein and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (ACT) in women with Her 2/neu negative axillary lymph node positive early breast cancer[J]. Cancer Res, 2009,77:1158 -1161.
  • 6Latifzadeh SZ,Salimi M, Naghnaeian M,et al. Dose dense(DD) two weekly docetaxel/doxorubicin/eyclopbosphamide (TAC) with G CSF support compared to standard adjuvant TAC in breast cancer patients[J]. Clin Oncol, 2008,26:628-632.
  • 7Eiermann W, Pienkowski T, Crown J, et al. BCIRG 005 main efficacy analysis: a phase Ⅲ randomized trial comparing do cetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubiein and eyelophosphamlde followed by docetaxel (ACT) in women with Her-2/neu negative axillary lymph node positive early breast cancer [J]. Cancer Res, 2009,69-77.
  • 8Tetnple RJ, Himmel MH. Safety of newly approved drugs: implications for prescribing [ J ]. JAMA, 2002, 287 ( 17 ) :2273-2275.
  • 9Bénichou C. Criteria of drug-indueed liver disorders. Report of an international consensus meeting [ J ]. J Hepatol, 1990, 11 (2) : 272-276.
  • 10Danan G, Bénichou C. Causality assessment of adverse re- actions to drugs- Ⅰ. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries [ J]. J Clin Epidemiol, 1993, 46 ( 11 ) : 1323-1330.

共引文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部